Every Form 4 that Mainz Biomed NV (MYNZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MYNZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYNZ filings page.
Ben-Tzvi Avraham reported acquisition or exercise transactions in this Form 4 filing.
Quantum Cyber N.V. director Ben-Tzvi Avraham reported receiving a grant of 137,141 Ordinary Shares on May 8, 2026. The award was recorded at a price of $0.00 per share, indicating a non-cash share grant rather than a market purchase. Following this transaction, his directly held stake increased to 139,141 Ordinary Shares, reflecting a compensation-related equity award and not an open-market trade.
NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.
Quantum Cyber N.V. director Natan David received a grant of ordinary shares as compensation. On May 8, 2026, he was awarded 137,141 ordinary shares at a stated price of $0.00 per share, bringing his directly held stake to 137,141 shares after the transaction.
Quantum Cyber N.V. Chief Executive Officer David E. Lazar reported new preferred share holdings and no beneficial ownership of ordinary shares. As of April 22, 2026, he beneficially owns 0 ordinary shares.
On that date, he was granted 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares at $1.50 per share, for an additional purchase price of $3,000,000. These Second Closing Shares follow a prior purchase of 1,000,000 Series A, 1,000,000 Series B, and 1,000,000 Series C Preferred Shares at $1.00 per share, totaling $3,000,000.
After stockholder approval on April 22, 2026, each First Closing Share is convertible into 9 ordinary shares and each Second Closing Share is convertible into 225 ordinary shares at the reporting person’s option for no additional consideration. Stockholders also approved increasing authorized ordinary shares to at least 900,000,000, a reverse stock split, conversion of all Preferred Shares into ordinary shares in compliance with Nasdaq rules, and election of Lazar and his designees to the board. Each class of Preferred Stock is perpetual with no expiration date.
Mainz Biomed director David E. Lazar reported a major preferred share investment. On February 13, 2026, he entered a securities purchase agreement to acquire 1,000,000 Series A, 1,000,000 Series B, and 1,000,000 Series C Preferred Shares at $1.00 per share, for a total of $3,000,000.
The footnotes state he will also acquire, at a later closing following stockholder approval, 1,000,000 Series D and 1,000,000 Series E Preferred Shares at $1.50 per share for an additional $3,000,000. The preferred shares are not convertible into ordinary shares until stockholders approve an increase in authorized ordinary shares to at least 900,000,000, a reverse stock split, Nasdaq compliance for conversion, and the election of Lazar and his designees to the board.
After this stockholder approval, each First Closing Share will be convertible into 9 ordinary shares and each Second Closing Share into 225 ordinary shares at Lazar’s option for no additional consideration. The filing notes that no ordinary shares are currently beneficially owned and that each class of preferred stock is perpetual with no expiration date.
Caragol William J reported acquisition or exercise transactions in this Form 4 filing.
MAINZ BIOMED N.V. Chief Financial Officer William J. Caragol received a grant of 290,000 Ordinary Shares on February 13, 2026 as an equity award. The shares were granted at a price of $0.00 per share under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid.
Following this award, Caragol directly owns a total of 367,899 Ordinary Shares. A separate footnote notes that 77,899 employee stock options were previously granted and reported on a Form 3 filed January 26, 2026.
Dreismann Heinrich reported acquisition or exercise transactions in this Form 4 filing.
Mainz Biomed N.V. director Heinrich Dreismann was granted 45,000 Ordinary Shares on February 13, 2026. The shares were issued as a grant under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, and the footnotes state that no cash consideration was paid for this award.
Following this equity grant, Dreismann directly owns 64,700 Ordinary Shares. A separate footnote notes that 19,700 employee stock options were previously granted and reported on a Form 3 filed on January 26, 2026.
Tibbitts Gregory J reported acquisition or exercise transactions in this Form 4 filing.
Mainz Biomed N.V. director Gregory J. Tibbitts reported an equity award of 45,000 Ordinary Shares on February 13, 2026. The shares were granted as restricted stock under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid for the award.
Following this grant, Tibbitts beneficially owned a total of 55,875 Ordinary Shares. In a related footnote, the company notes that 10,875 employee stock options had previously been granted and were reported earlier on a Form 3 filed on January 26, 2026.
MAINZ BIOMED N.V. reported that Chief Executive Officer Guido Baechler acquired 440,000 Ordinary Shares on February 13, 2026 through a grant of restricted shares under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid. Following this equity award, his directly held Ordinary Shares increased to 605,058. A footnote adds that 6,362 Ordinary Shares and 158,696 employee stock options had been granted earlier and were previously reported on a prior Form 3.
Mainz Biomed N.V. director Kevin Donahue reported buying common stock in the company. On October 17, 2025, he purchased 685,000 shares at a price of $1.51 per share, leaving him with a total of 685,000 shares beneficially owned in a direct account after the transaction. This Form 4/A is an amendment correcting a prior insider transaction report that was originally filed on 01/16/2026.
Mainz Biomed N.V. insider Donahue Kevin Michael, identified as a 10% owner, reported buying common stock. On 10/17/2025, he acquired 643,850 shares of Mainz Biomed common stock in a single open-market or private purchase transaction reported with code "P." Following this transaction, his directly held beneficial ownership stands at 643,850 shares.